Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT.

Ito M, Oishi R, Fukunaga M, Sone T, Sugimoto T, Shiraki M, Nishizawa Y, Nakamura T.

Osteoporos Int. 2014 Mar;25(3):1163-72. doi: 10.1007/s00198-013-2596-y. Epub 2013 Dec 18.

2.

Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.

Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T.

Bone. 2011 Sep;49(3):328-34. doi: 10.1016/j.bone.2011.05.002. Epub 2011 May 15.

3.

Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.

Bone. 2005 Jun;36(6):948-58.

PMID:
15878318
4.

The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk.

Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T.

Bone. 2014 Jul;64:75-81. doi: 10.1016/j.bone.2014.04.004. Epub 2014 Apr 13.

5.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.

PMID:
25393645
6.
7.

Femoral strength in osteoporotic women treated with teriparatide or alendronate.

Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K.

Bone. 2012 Jan;50(1):165-70. doi: 10.1016/j.bone.2011.10.002. Epub 2011 Oct 17.

PMID:
22015818
8.

Age-related changes in bone density, geometry and biomechanical properties of the proximal femur: CT-based 3D hip structure analysis in normal postmenopausal women.

Ito M, Nakata T, Nishida A, Uetani M.

Bone. 2011 Mar 1;48(3):627-30. doi: 10.1016/j.bone.2010.11.007. Epub 2010 Nov 16.

PMID:
21087686
9.

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M.

Osteoporos Int. 2014 Mar;25(3):1173-80. doi: 10.1007/s00198-013-2516-1. Epub 2013 Oct 10.

10.

Effect of monthly ibandronate on hip structural geometry in men with low bone density.

Genant HK, Lewiecki EM, Fuerst T, Fries M.

Osteoporos Int. 2012 Jan;23(1):257-65. doi: 10.1007/s00198-011-1732-9. Epub 2011 Aug 3.

PMID:
21811866
11.

Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.

J Clin Endocrinol Metab. 2012 Sep;97(9):3097-106. doi: 10.1210/jc.2011-3479. Epub 2012 Jun 20.

PMID:
22723322
12.

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.

J Bone Miner Metab. 2008;26(6):624-34. doi: 10.1007/s00774-008-0871-3. Epub 2008 Nov 1.

PMID:
18979163
13.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

14.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
15.

Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.

Gonnelli S, Martini G, Caffarelli C, Salvadori S, Cadirni A, Montagnani A, Nuti R.

Osteoporos Int. 2006 Oct;17(10):1524-31. Epub 2006 Jun 9.

PMID:
16767526
16.

Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K.

Osteoporos Int. 2016 Apr;27(4):1441-50. doi: 10.1007/s00198-015-3377-6. Epub 2015 Nov 2.

PMID:
26525045
17.

[Once-weekly teriparatide treatment on osteoporosis].

Nakano T.

Clin Calcium. 2014 Jan;24(1):100-5. doi: CliCa1401100105. Review. Japanese.

PMID:
24369286
18.

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.

Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.

19.

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.

Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C.

J Clin Densitom. 2008 Jul-Sep;11(3):351-9. doi: 10.1016/j.jocd.2008.04.001. Epub 2008 May 20.

PMID:
18495508
20.

Analysis of daily teriparatide treatment for osteoporosis in men.

Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.

Osteoporos Int. 2015 Apr;26(4):1303-9. doi: 10.1007/s00198-014-3001-1. Epub 2015 Jan 8. Erratum in: Osteoporos Int. 2015 Aug;26(8):2221.

PMID:
25567777

Supplemental Content

Support Center